| Authors: |
Belmar NA; Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063., Chan SW; Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063., Fox MI; Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063., Samayoa JA; Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063., Stickler MM; Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063., Tran NN; Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063., Akamatsu Y; Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063., Hollenbaugh D; Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063., Harding FA; Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063., Alvarez HM; Oncology Biologics Department, AbbVie Biotherapeutics Inc., Redwood City, CA 94063 hamsell.alvarezjares@abbvie.com. |